Aurinia Pharmaceuticals Inc. (AUPH) — SEC Filings
Aurinia Pharmaceuticals Inc. (AUPH) — 25 SEC filings. Latest: 10-Q (Nov 4, 2025). Includes 6 10-Q, 6 8-K, 3 DEFA14A.
View Aurinia Pharmaceuticals Inc. on SEC EDGAR
Overview
Aurinia Pharmaceuticals Inc. (AUPH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 4, 2025: Aurinia Pharmaceuticals Inc. reported a significant increase in net income for the nine months ended September 30, 2025, reaching $76.408 million, up from $4.323 million in the same period of 2024. This surge was primarily driven by a substantial increase in net product sales, which grew to $197.172
Sentiment Summary
Across 25 filings, the sentiment breakdown is: 1 bullish, 23 neutral, 1 mixed. The dominant filing sentiment for Aurinia Pharmaceuticals Inc. is neutral.
Filing Type Overview
Aurinia Pharmaceuticals Inc. (AUPH) has filed 6 10-Q, 6 8-K, 3 DEFA14A, 2 DEF 14A, 2 10-K, 2 SC 13G/A, 1 SC 13D, 1 10-K/A, 1 SC 13D/A, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (25)
Risk Profile
Risk Assessment: Of AUPH's 22 recent filings, 0 were flagged as high-risk, 11 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $205.941M |
| Net Income | $76.408M |
| EPS | $0.57 |
| Debt-to-Equity | 0.44 |
| Cash Position | $73.189M |
| Operating Margin | 34.8% |
| Total Assets | $527.528M |
| Total Debt | $71.976M |
Key Executives
- Kevin Tang
- SAE KYOUNG HUH
- SEOUNG EUN HUH
- CHIN KYU HUH
Industry Context
The autoimmune disease market, particularly for lupus nephritis, is experiencing significant growth driven by unmet medical needs and advancements in targeted therapies. Aurinia's LUPKYNIS is a key player in this space, facing competition from established treatments and emerging pipeline candidates from other biopharmaceutical companies.
Top Tags
corporate-governance (5) · pharmaceuticals (5) · 10-Q (4) · financials (4) · sec-filing (4) · Aurinia Pharmaceuticals (4) · proxy-statement (3) · Pharmaceuticals (2) · 8-K (2) · 10-K (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $76.408M | for nine months ended Sept 30, 2025, up from $4.323M in 2024 |
| Net Product Sales | $197.172M | for nine months ended Sept 30, 2025, up from $158.604M in 2024 |
| Total Revenue | $205.941M | for nine months ended Sept 30, 2025, up from $175.266M in 2024 |
| Total Operating Expenses | $134.266M | for nine months ended Sept 30, 2025, down from $178.284M in 2024 |
| Selling, General and Administrative Expenses | $72.539M | for nine months ended Sept 30, 2025, down from $134.996M in 2024 |
| Cash, Cash Equivalents and Restricted Cash | $73.189M | as of Sept 30, 2025, down from $83.433M at Dec 31, 2024 |
| Repurchase of Common Shares | $98.156M | for nine months ended Sept 30, 2025 |
| Common Shares Outstanding | 131,840,559 | as of November 3, 2025 |
| Basic Earnings Per Share | $0.57 | for nine months ended Sept 30, 2025, up from $0.03 in 2024 |
| Inventory, net | $44.793M | as of Sept 30, 2025, up from $39.228M at Dec 31, 2024 |
| Q2 2025 Product Revenue | $39.2M | Increased 30.2% from Q2 2024 |
| H1 2025 Product Revenue | $75.8M | Increased 29.6% from H1 2024 |
| Q2 Product Revenue Growth | 30.2% | Year-over-year increase for the quarter |
| H1 Product Revenue Growth | 29.6% | Year-over-year increase for the six-month period |
| Reporting Period | 2025 Q1 | First quarter of 2025 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Aurinia Pharmaceuticals Inc. (AUPH)?
Aurinia Pharmaceuticals Inc. has 25 recent SEC filings from Jan 2024 to Nov 2025, including 6 10-Q, 6 8-K, 3 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AUPH filings?
Across 25 filings, the sentiment breakdown is: 1 bullish, 23 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Aurinia Pharmaceuticals Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Aurinia Pharmaceuticals Inc. (AUPH) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Aurinia Pharmaceuticals Inc.?
Key financial highlights from Aurinia Pharmaceuticals Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for AUPH?
The investment thesis for AUPH includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Aurinia Pharmaceuticals Inc.?
Key executives identified across Aurinia Pharmaceuticals Inc.'s filings include Kevin Tang, SAE KYOUNG HUH, SEOUNG EUN HUH, CHIN KYU HUH.
What are the main risk factors for Aurinia Pharmaceuticals Inc. stock?
Of AUPH's 22 assessed filings, 0 were flagged high-risk, 11 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Aurinia Pharmaceuticals Inc.?
Forward guidance and predictions for Aurinia Pharmaceuticals Inc. are extracted from SEC filings as they are enriched.